Shiota M, Galassetti P, Monohan M, Neal D W, Cherrington A D
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0615, USA.
Diabetes. 1998 Jun;47(6):867-73. doi: 10.2337/diabetes.47.6.867.
Fructose activates glucokinase by releasing the enzyme from its inhibitory protein in liver. To examine the importance of acute activation of glucokinase in regulating hepatic glucose uptake, the effect of intraportal infusion of a small amount of fructose on net hepatic glucose uptake (NHGU) was examined in 42 h-fasted conscious dogs. Isotopic ([3-3H] and [U-14C]glucose) and arteriovenous difference methods were used. Each study consisted of an equilibration period (-90 to -30 min), a control period (-30 to 0 min), and a hyperglycemic/hyperinsulinemic period (0-390 min). During the latter period, somatostatin (489 pmol x kg(-1) x min(-1)) was given, along with intraportal insulin (7.2 pmol x kg(-1) x min(-1)) and glucagon (0.5 ng x kg(-1) x min(-1)). In this way, the liver sinusoidal insulin level was fixed at four times basal (456 +/- 60 pmol/l), and liver sinusoidal glucagon level was kept basal (46 +/- 6 ng/l). Glucose was infused through a peripheral vein to create hyperglycemia (12.5 mmol/l plasma). Hyperglycemic hyperinsulinemia (no fructose) switched net hepatic glucose balance (micromoles per kilogram per minute) from output (11.3 +/- 1.4) to uptake (14.7 +/- 1.7) and net lactate balance (micromoles per kilogram per minute) from uptake (6.5 +/- 2.1) to output (4.4 +/- 1.5). Fructose was infused intraportally at a rate of 1.7, 3.3, or 6.7 micromol x kg(-1) x min(-1), starting at 120, 210, or 300 min, respectively. In the three periods, portal blood fructose increased from <6 to 113 +/- 14, 209 +/- 29, and 426 +/- 62 micromol/l, and net hepatic fructose uptake increased from 0.03 +/- 0.01 to 1.3 +/- 0.4, 2.3 +/- 0.7, and 5.1 +/- 0.6 micromol x kg(-1) x min(-1), respectively. NHGU increased to 41 +/- 3, 54 +/- 5, and 69 +/- 8 micromol x kg(-1) x min(-1), respectively, and net hepatic lactate output increased to 11.0 +/- 3.2, 15.3 +/- 2.7, and 22.4 +/- 2.8 micromol x kg(-1) x min(-1) in the three fructose periods, respectively. The amount of [3H]glucose incorporated into glycogen was equivalent to 69 +/- 3% of [3H]glucose taken up by the liver. These data suggest that glucokinase translocation within the hepatocyte is a major determinant of hepatic glucose uptake by the dog in vivo.
果糖通过将肝脏中的葡萄糖激酶从其抑制蛋白上释放出来而激活该酶。为了研究葡萄糖激酶急性激活在调节肝脏葡萄糖摄取中的重要性,在禁食42小时的清醒犬中,研究了门静脉内输注少量果糖对肝脏净葡萄糖摄取(NHGU)的影响。采用了同位素([3-³H]和[U-¹⁴C]葡萄糖)和动静脉差值法。每项研究包括一个平衡期(-90至-30分钟)、一个对照期(-30至0分钟)和一个高血糖/高胰岛素期(0 - 39分钟)。在后一时期,给予生长抑素(489 pmol·kg⁻¹·min⁻¹),同时门静脉内给予胰岛素(7.2 pmol·kg⁻¹·min⁻¹)和胰高血糖素(0.5 ng·kg⁻¹·min⁻¹)。通过这种方式,肝脏窦状隙胰岛素水平固定在基础水平的四倍(456±60 pmol/L),肝脏窦状隙胰高血糖素水平保持在基础水平(46±6 ng/L)。通过外周静脉输注葡萄糖以产生高血糖(血浆12.5 mmol/L)。高血糖高胰岛素血症(无果糖)使肝脏净葡萄糖平衡(微摩尔/千克/分钟)从输出(11.3±1.4)转变为摄取(14.7±1.7),肝脏净乳酸平衡(微摩尔/千克/分钟)从摄取(6.5±2.1)转变为输出(4.4±1.5)。果糖分别以1.7、3.3或6.7微摩尔·千克⁻¹·分钟⁻¹的速率门静脉内输注,分别在120、210或300分钟开始。在这三个时期,门静脉血果糖从<6增加到113±14、209±29和426±62微摩尔/升,肝脏净果糖摄取分别从0.03±0.01增加到1.3±0.4、2.3±0.7和5.1±0.6微摩尔·千克⁻¹·分钟⁻¹。在三个果糖时期,NHGU分别增加到41±3、54±5和69±8微摩尔·千克⁻¹·分钟⁻¹,肝脏净乳酸输出分别增加到11.0±3.2、15.3±2.7和22.4±2.8微摩尔·千克⁻¹·分钟⁻¹。掺入糖原中的[³H]葡萄糖量相当于肝脏摄取的[³H]葡萄糖的69±3%。这些数据表明,肝细胞内葡萄糖激酶的转位是犬体内肝脏葡萄糖摄取的主要决定因素。